137 related articles for article (PubMed ID: 3718817)
1. 9-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures.
Scott CA; Westmacott D; Broadhurst MJ; Thomas GJ; Hall MJ
Br J Cancer; 1986 May; 53(5):595-600. PubMed ID: 3718817
[TBL] [Abstract][Full Text] [Related]
2. Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A.
Coley HM; Twentyman PR; Workman P
Cancer Chemother Pharmacol; 1989; 24(5):284-90. PubMed ID: 2547527
[TBL] [Abstract][Full Text] [Related]
3. Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins.
Umezawa K; Kunimoto S; Takeuchi T
Biomed Pharmacother; 1987; 41(5):206-13. PubMed ID: 2444279
[TBL] [Abstract][Full Text] [Related]
4. Evidence of multifactorial mechanisms in an adriamycin-resistant HL-60 promyelocytic leukemia cell line.
Burres NS; Myers MT; Sartorelli AC
Cancer Biochem Biophys; 1988 Jul; 10(1):47-57. PubMed ID: 3224331
[TBL] [Abstract][Full Text] [Related]
5. Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines.
Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Kimura I
Acta Med Okayama; 1992 Aug; 46(4):249-56. PubMed ID: 1442149
[TBL] [Abstract][Full Text] [Related]
6. [New anthracycline antibiotics and derivatives].
Tatsuta K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2640-52. PubMed ID: 6594977
[TBL] [Abstract][Full Text] [Related]
7. Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.
Hill BT; Dennis LY; Li XT; Whelan RD
Cancer Chemother Pharmacol; 1985; 14(3):194-201. PubMed ID: 3858013
[TBL] [Abstract][Full Text] [Related]
8. Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance.
Coley HM; Twentyman PR; Workman P
Anticancer Drug Des; 1992 Dec; 7(6):471-81. PubMed ID: 1337431
[TBL] [Abstract][Full Text] [Related]
9. Enhanced topoisomerase II targeting by annamycin and related 4-demethoxy anthracycline analogues.
Trevino AV; Woynarowska BA; Herman TS; Priebe W; Woynarowski JM
Mol Cancer Ther; 2004 Nov; 3(11):1403-10. PubMed ID: 15542779
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory activity of four demethoxy fluorinated anthracycline analogs against five human-tumor cell lines.
Horton D; Khare A
Bioorg Med Chem Lett; 2010 Nov; 20(21):6179-81. PubMed ID: 20850305
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of adriamycin accumulation and effectiveness in adriamycin-resistant cells by aclacinomycin A.
Tapiero H; Boulé D; Trincal G; Fourcade A; Lampidis TJ
Leuk Res; 1988; 12(5):411-8. PubMed ID: 3164087
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin.
Hong WS; Jung HY; Yang SK; Kim HR; Min YI
Anticancer Res; 1997; 17(5A):3613-6. PubMed ID: 9413212
[TBL] [Abstract][Full Text] [Related]
13. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity.
Faderl S; Estrov Z; Kantarjian HM; Harris D; Van Q; Fokt I; Przewloka T; Godlewski C; Woynarowski JM; Priebe W
Anticancer Res; 2001; 21(6A):3777-84. PubMed ID: 11911247
[TBL] [Abstract][Full Text] [Related]
14. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
Watanabe M; Komeshima N; Nakajima S; Tsuruo T
Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
16. [Studies on the mechanism of drug resistance in tumor cells and a new antitumor antibiotic].
Tanaka N
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2666-73. PubMed ID: 6210060
[TBL] [Abstract][Full Text] [Related]
17. The in vitro effects and cross-resistance patterns of some novel anthracyclines.
Twentyman PR; Fox NE; Wright KA; Workman P; Broadhurst MJ; Martin JA; Bleehen NM
Br J Cancer; 1986 May; 53(5):585-94. PubMed ID: 3459509
[TBL] [Abstract][Full Text] [Related]
18. N-benzyladriamycin-14-valerate (AD 198)-resistant cells exhibit highly selective cross-resistance to other anthracyclines that circumvent multidrug resistance.
Lothstein L; Hosey LM; Sweatman TW; Koseki Y; Dockter M; Priebe W
Oncol Res; 1993; 5(6-7):229-34. PubMed ID: 7907237
[TBL] [Abstract][Full Text] [Related]
19. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
[TBL] [Abstract][Full Text] [Related]
20. Studies on aclacinomycin A resistance in mouse lymphoblastoma.
Nishimura T; Suzuki H; Muto K; Tanaka Y; Tanaka N
J Antibiot (Tokyo); 1980 Jul; 33(7):737-43. PubMed ID: 6931828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
